National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity

Susanna N Visser1, Catherine A Lesesne, Ruth Perou

  • 1National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop E-88, Atlanta, GA 30333, USA. svisser@cdc.gov

Pediatrics
|February 3, 2007
PubMed

Insights

Medication treatment for attention-deficit/hyperactivity disorder (ADHD) was linked to younger age, psychological difficulties, and recent healthcare contact for both boys and girls. Factors like income and paternal mental health also showed gender-specific associations with ADHD medication use.

Area of Science:

  • Child and Adolescent Psychiatry
  • Neurodevelopmental Disorders
  • Public Health

Background:

  • Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder affecting children and adolescents.
  • Understanding factors associated with medication treatment is crucial for optimizing care and support.

Purpose of the Study:

  • To identify child and family-level characteristics associated with medication treatment for ADHD.
  • To explore gender-specific factors influencing ADHD medication use.

Main Methods:

  • Utilized data from the National Survey of Children's Health (n=79,264).
  • Employed gender-specific logistic regression models to analyze associations with current medication status.
  • Weighted data to account for the complex survey design.

Main Results:

  • Nationally, 7.8% of youth had an ADHD diagnosis, and 4.3% were on medication.
  • Medication treatment was associated with white race, younger age, English as home language, healthcare coverage, recent healthcare contact, and psychological difficulties.
  • Gender-specific analyses revealed younger age, psychological difficulties, and recent healthcare contact were common factors; income and healthcare access were significant for boys, while paternal mental health was significant for girls.

Conclusions:

  • Younger age, psychological difficulties, and recent healthcare contact are key predictors of ADHD medication treatment across genders.
  • Healthcare access and income for boys, and paternal mental health for girls, represent important gender-specific correlates of medication use.
  • Further research is needed to understand the pathway from ADHD burden to treatment and support services.
Abstract

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...